AsiDNA™ Letter – No. 2

AsiDNA™ Letter – No. 2

Role of AsiDNA™ in the new combination strategies

Ladies, Gentlemen and shareholders

The complexity and diversity of cancers require multiple therapeutic approaches. The combination of several anti-cancer agents has become the norm in oncology, especially to treat the very aggressive or resistant cancers.

Thanks to its original anti-tumor activity and its good tolerance already clinically demonstrated, AsiDNA™ is ideally positioned to play a key role in new combination strategies aiming to treat these cancers, for which the medical needs remain significant.

Read the Letter